Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients

International Journal of Antimicrobial Agents

Volumn 41, Issue 1, 2013, Pages 52-56

  Cheatham, S Christian ^a   Fleming, Megan R ^b   Healy, Daniel P ^c   Chung, Christina E K ^d   Shea, Katherine M ^e   Humphrey, Melissa L ^d   Kays, Michael B ^d  

^a St Francis Hospital   (United States)

^b METHODIST DALLAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d PURDUE UNIVERSITY   (United States)

^e University Medical Center Brackenridge   (United States)

Author keywords

Obesity; Pharmacodynamics; Pharmacokinetics; Piperacillin; Prolonged infusion; Tazobactam

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; BLOOD SAMPLING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTI-BACTERIAL AGENTS; BLOOD CHEMICAL ANALYSIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OBESITY; PENICILLANIC ACID; PIPERACILLIN; TIME FACTORS;

EID: 84871667901     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.09.004     Document Type: Conference Paper

References (30)

1. World Health Organization. Obesity and overweight. Geneva, Switzerland: WHO; 2012. Fact sheet No. 311. http://www.who.int/mediacentre/factsheets/fs311/ en [accessed 28.06.12].
2. K.M. Flegal, M.D. Carroll, C.L. Ogden, and L.R. Curtin Prevalence and trends in obesity among US adults, 1999-2008 JAMA 313 2010 235 241
3. Y.C. Wang, K. McPherson, T. Marsh, S.L. Gortmaker, and M. Brown Health and economic burden of the projected obesity trends in the USA and the UK Lancet 378 2011 815 825
4. M.E. Falagas, and M. Kompoti Obesity and infection Lancet Infect Dis 6 2006 438 446
5. P.S. Choban, R. Heckler, J.C. Burge, and L. Flancbaum Increased incidence of nosocomial infections in obese surgical patients Am Surg 6 1995 1001 1005
6. M. Lofgren, I.S. Poromaa, J.H. Stjerndahl, and B. Renstrom Postoperative infections and antibiotic prophylaxis for hysterectomy in Sweden: a study by the Swedish National Register for Gynecologic Surgery Acta Obstet Gynecol Scand 83 2004 1202 1207
7. T.D. Crabtree, J.E. Codd, V.J. Fraser, M.S. Bailey, M.A. Olsen, and R.J. Damiano Jr. Multivariate analysis of risk factors for deep and superficial sternal infection after coronary artery bypass grafting at a tertiary care medical center Semin Thorac Cardiovasc Surg 16 2004 53 61
8. M.P. Pai, and D.T. Bearden Antimicrobial dosing considerations in obese adult patients Pharmacotherapy 27 2007 1081 1091
9. T.P. Lodise, B.M. Lomaestro, and G.L. Drusano Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics Pharmacotherapy 26 2006 1320 1332
10. A. Gin, L. Dilay, J.A. Karlowsky, A. Walkty, E. Rubinstein, and G.G. Zhanel Piperacillin/tazobactam: a β-lactam/β-lactamase inhibitor combination Expert Rev Anti Infect Ther 5 2007 365 383
11. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416
12. Zosyn (piperacillin/tazobactam) prescribing information. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2012.
13. T.P. Lodise, B. Lomaestro, and G.L. Drusano Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy Clin Infect Dis 44 2007 357 363
14. K.M. Shea, S.C. Cheatham, M.F. Wack, D.W. Smith, K.M. Sowinski, and M.B. Kays Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using steady-state pharmacokinetic data from hospitalized patients Ann Pharmacother 43 2009 1747 1754
15. D. Newman, M.H. Scheetz, O.A. Adeyemi, M. Montevecchi, D.P. Nicolau, and G.A. Noskin Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual Ann Pharmacother 41 2007 1734 1739
16. J.A. Demirovic, A.B. Pai, and M.P. Pai Estimation of creatinine clearance in morbidly obese patients Am J Health Syst Pharm 66 2009 642 648
17. V. Augey, P.Y. Grosse, G. Albert, M. Audran, and F. Bressolle High-performance liquid chromatographic determination of tazobactam and piperacillin in human plasma and urine J Chromatogr B Biomed Appl 682 1996 125 136
18. B.C. McWhinney, S.C. Wallis, T. Hillister, J.A. Roberts, J. Lipman, and J.P. Ungerer Analysis of 12 β-lactam antibiotics in human plasma by HPLC with ultraviolet detection J Chromatogr B Analyt Technol Biomed Life Sci 878 2010 2039 2043
19. A. Kim, C.A. Sutherland, J.L. Kuti, and D.P. Nicolau Optimal dosing of piperacillin/tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 27 2007 1490 1497
20. A.H. Strayer, D.H. Gilbert, P. Pivarnik, A.A. Medeiros, S.H. Zinner, and M.N. Dudley Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection Antimicrob Agents Chemother 38 1994 2351 2356
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. Document M100-S22. Wayne, PA: CLSI; 2012.
22. T.H. Dellit, R.C. Owens, J.E. McGowan Jr., D.N. Gerding, R.A. Weinstein, and J.P. Burke Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship Clin Infect Dis 44 2007 159 177
23. T.L. Zakrison, D.A. Hille, and N. Namias Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam Surg Infect (Larchmt) 13 2012 38 42
24. K.M. Shea, S.C. Cheatham, M.F. Wack, D.W. Smith, K.M. Sowinski, and M.B. Kays Steady-state pharmacokinetics and pharmacodynamics of piperacillin/ tazobactam administered by prolonged infusion in hospitalized patients Int J Antimicrob Agents 34 2009 429 433
25. P.D. Lister, A.M. Prevan, and C.C. Sanders Importance of β-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam Antimicrob Agents Chemother 41 1997 721 727
26. G. Leleu, M.D. Kitzis, J.M. Vallois, L. Gutmann, and J.M. Decazes Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum β-lactamase Antimicrob Agents Chemother 38 1994 195 199
27. M. Dudley, D. Gilbert, K. Rana, A. Carter, A. Medeiros, and S. Zinner Use of an in vitro pharmacodynamic model to determine optimal dose and dosing interval of β-lactamase inhibitor combinations (BLICs) 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 17-20 September 1995, San Francisco, CA 1995 ASM Press Washington, DC [Abstract A63]
28. M. Kinzig, F. Sorgel, B. Brismar, and C.E. Nord Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery Antimicrob Agents Chemother 36 1992 1997 2004
29. S.S. Jhee, J.W. Kern, J.P. Burm, A.E. Yellin, and M.A. Gill Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections Pharmacotherapy 15 1995 472 478
30. C. Buck, N. Bertram, T. Ackermann, T. Sauerbruch, H. Derendorf, and W.D. Paar Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion Int J Antimicrob Agents 25 2005 62 67